Allergan Receives FDA Approval for Acuvail Ophthalmic Solution for the Treatment of Pain and Inflammation Following Cataract Surgery
July 23, 2009
IRVINE, Calif.--(BUSINESS WIRE)--Jul 23, 2009 - Allergan, Inc. today
announced that the United States Food and Drug Administration (FDA)
has approved Acuvail (ketorolac tromethamine ophthalmic solution)
0.45%, an advanced, preservative-free formulation of ketorolac, a
nonsteroidal anti-inflammatory drug (NSAID) indicated for the
treatment of pain and inflammation following cataract surgery.
IRVINE, Calif.--(BUSINESS WIRE)--Jul 23, 2009 - Allergan, Inc. today
announced that the United States Food and Drug Administration (FDA)
has approved Acuvail (ketorolac tromethamine ophthalmic solution)
0.45%, an advanced, preservative-free formulation of ketorolac, a
nonsteroidal anti-inflammatory drug (NSAID) indicated for the
treatment of pain and inflammation following cataract surgery.
Comentarios
Publicar un comentario